{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T19:46:13Z","timestamp":1793216773771,"version":"4.5.0"},"reference-count":74,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2017,8,1]],"date-time":"2017-08-01T00:00:00Z","timestamp":1501545600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","semarthritisrheumatism.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2017,8]]},"DOI":"10.1016\/j.semarthrit.2017.02.003","type":"journal-article","created":{"date-parts":[[2017,2,10]],"date-time":"2017-02-10T12:30:32Z","timestamp":1486729832000},"page":"133-142","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":34,"title":["Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study"],"prefix":"10.1016","volume":"47","author":[{"given":"Jeffrey A.","family":"Sparks","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Medha","family":"Barbhaiya","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth W.","family":"Karlson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susan Y.","family":"Ritter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Soumya","family":"Raychaudhuri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cassandra C.","family":"Corrigan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengxin","family":"Lu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Selhub","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel I.","family":"Chasman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nina P.","family":"Paynter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul M.","family":"Ridker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel H.","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.semarthrit.2017.02.003_bib1","doi-asserted-by":"crossref","first-page":"845496","DOI":"10.1155\/2011\/845496","article-title":"Cost effectiveness analysis of disease-modifying antirheumatic drugs in rheumatoid arthritis. A systematic review literature","volume":"2011","author":"Benucci","year":"2011","journal-title":"Int J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib2","first-page":"572","article-title":"Methotrexate (MTX) pathway gene polymorphisms and their effects on MTX toxicity in Caucasian and African American patients with rheumatoid arthritis","volume":"35","author":"Ranganathan","year":"2008","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1002\/art.39480","article-title":"2015 American College of Rheumatology Guideline for the treatment of rheumatoid arthritis","volume":"68","author":"Singh","year":"2016","journal-title":"Arthritis Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib4","doi-asserted-by":"crossref","first-page":"864","DOI":"10.1002\/art.22353","article-title":"Long-term impact of early treatment on radiographic progression in rheumatoid arthritis: a meta-analysis","volume":"55","author":"Finckh","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib5","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1056\/NEJM198503283121303","article-title":"Efficacy of low-dose methotrexate in rheumatoid arthritis","volume":"312","author":"Weinblatt","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib6","first-page":"238","article-title":"Longterm prospective study of methotrexate in rheumatoid arthritis: conclusion after 132 months of therapy","volume":"25","author":"Weinblatt","year":"1998","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib7","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1002\/art.37723","article-title":"Propensity-adjusted association of methotrexate with overall survival in rheumatoid arthritis","volume":"65","author":"Wasko","year":"2013","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib8","doi-asserted-by":"crossref","first-page":"1173","DOI":"10.1016\/S0140-6736(02)08213-2","article-title":"Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study","volume":"359","author":"Choi","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib9","doi-asserted-by":"crossref","DOI":"10.1016\/j.ahj.2013.03.018","article-title":"Rationale and design of the Cardiovascular Inflammation Reduction Trial: a test of the inflammatory hypothesis of atherothrombosis","volume":"166","author":"Everett","year":"2013","journal-title":"Am Heart J"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib10","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1191\/096120301666080831","article-title":"Methotrexate therapy in systemic lupus erythematosus","volume":"10","author":"Sato","year":"2001","journal-title":"Lupus"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib11","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1136\/ard.2011.150995","article-title":"A systematic literature review of drug therapies for the treatment of psoriatic arthritis: current evidence and meta-analysis informing the EULAR recommendations for the management of psoriatic arthritis","volume":"71","author":"Ash","year":"2012","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib12","doi-asserted-by":"crossref","first-page":"1366","DOI":"10.1002\/art.21762","article-title":"Methotrexate pharmacogenetics: the first step toward individualized therapy in rheumatoid arthritis","volume":"54","author":"Ranganathan","year":"2006","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib13","doi-asserted-by":"crossref","first-page":"1100","DOI":"10.1136\/ard.2008.093690","article-title":"Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib14","doi-asserted-by":"crossref","first-page":"822","DOI":"10.1002\/art.1780290702","article-title":"The safety and efficacy of the use of methotrexate in long-term therapy for rheumatoid arthritis","volume":"29","author":"Kremer","year":"1986","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib15","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1093\/rheumatology\/28.2.147","article-title":"Prospective long term follow-up of methotrexate therapy in rheumatoid arthritis: toxicity, efficacy and radiological progression","volume":"28","author":"Hanrahan","year":"1989","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib16","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1002\/art.1780350203","article-title":"Long-term prospective study of the use of methotrexate in the treatment of rheumatoid arthritis. Update after a mean of 90 months","volume":"35","author":"Kremer","year":"1992","journal-title":"Arthritis Rheum"},{"issue":"5 Suppl. 61","key":"10.1016\/j.semarthrit.2017.02.003_bib17","first-page":"S95","article-title":"Side effects and management of side effects of methotrexate in rheumatoid arthritis","volume":"28","author":"Albrecht","year":"2010","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib18","doi-asserted-by":"crossref","first-page":"1443","DOI":"10.1136\/ard.2007.071092","article-title":"Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial)","volume":"66","author":"Verstappen","year":"2007","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib19","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1136\/ard.2004.023408","article-title":"Long term safety of methotrexate in routine clinical care: discontinuation is unusual and rarely the result of laboratory abnormalities","volume":"64","author":"Yazici","year":"2005","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib20","first-page":"1017","article-title":"Risk and management of liver toxicity during methotrexate treatment in rheumatoid and psoriatic arthritis: a systematic review of the literature","volume":"27","author":"Visser","year":"2009","journal-title":"Clin Exp Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib21","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1002\/art.1780370304","article-title":"Methotrexate for rheumatoid arthritis. Suggested guidelines for monitoring liver toxicity. American College of Rheumatology","volume":"37","author":"Kremer","year":"1994","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib22","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1136\/ard.2008.101378","article-title":"Elevated liver enzyme tests among patients with rheumatoid arthritis or psoriatic arthritis treated with methotrexate and\/or leflunomide","volume":"69","author":"Curtis","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib23","first-page":"1727","article-title":"Risk factors for methotrexate-induced abnormal laboratory monitoring results in patients with rheumatoid arthritis","volume":"31","author":"Kent","year":"2004","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib24","first-page":"1180","article-title":"Methotrexate-induced liver abnormalities in rheumatoid arthritis","volume":"16","author":"Bridges","year":"1989","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib25","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/0049-0172(89)90085-1","article-title":"Prospective analysis of liver biopsies before and after methotrexate therapy in rheumatoid patients","volume":"19","author":"Brick","year":"1989","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib26","doi-asserted-by":"crossref","first-page":"1457","DOI":"10.1002\/art.1780311201","article-title":"Histopathologic findings in the liver of rheumatoid arthritis patients treated with long-term bolus methotrexate","volume":"31","author":"Aponte","year":"1988","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib27","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1136\/thx.47.8.628","article-title":"Acute pneumonitis associated with low dose methotrexate treatment for rheumatoid arthritis: report of five cases and review of published reports","volume":"47","author":"Hargreaves","year":"1992","journal-title":"Thorax"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib28","first-page":"1043","article-title":"The relationship of preexisting lung disease to the development of methotrexate pneumonitis in patients with rheumatoid arthritis","volume":"22","author":"Golden","year":"1995","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib29","doi-asserted-by":"crossref","first-page":"1829","DOI":"10.1002\/art.1780401016","article-title":"Clinical, laboratory, radiographic, and histopathologic features of methotrexate-associated lung injury in patients with rheumatoid arthritis: a multicenter study with literature review","volume":"40","author":"Kremer","year":"1997","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib30","doi-asserted-by":"crossref","DOI":"10.1136\/bmj.h1269","article-title":"Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials","volume":"350","author":"Conway","year":"2015","journal-title":"Br Med J"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib31","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1136\/ard.53.7.434","article-title":"Methotrexate-related pulmonary complications in rheumatoid arthritis","volume":"53","author":"Barrera","year":"1994","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib32","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1093\/rheumatology\/35.5.441","article-title":"Occurrence of pulmonary complications during methotrexate therapy in rheumatoid arthritis","volume":"35","author":"Hilliquin","year":"1996","journal-title":"Br J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib33","doi-asserted-by":"crossref","first-page":"356","DOI":"10.7326\/0003-4819-127-5-199709010-00003","article-title":"Risk factors for methotrexate-induced lung injury in patients with rheumatoid arthritis. A multicenter, case\u2013control study. Methotrexate-Lung Study Group","volume":"127","author":"Alarcon","year":"1997","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib34","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/rheumatology\/41.3.262","article-title":"Investigation of the chronic pulmonary effects of low-dose oral methotrexate in patients with rheumatoid arthritis: a prospective study incorporating HRCT scanning and pulmonary function tests","volume":"41","author":"Dawson","year":"2002","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib35","doi-asserted-by":"crossref","first-page":"h1269","DOI":"10.1136\/bmj.h1269","article-title":"Methotrexate use and risk of lung disease in psoriasis, psoriatic arthritis, and inflammatory bowel disease: systematic literature review and meta-analysis of randomised controlled trials","volume":"350","author":"Conway","year":"2015","journal-title":"Br Med J"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib36","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1093\/rheumatology\/kem076","article-title":"Anti-rheumatic drug use and risk of serious infections in rheumatoid arthritis","volume":"46","author":"Bernatsky","year":"2007","journal-title":"Rheumatology (Oxford)"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib37","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1136\/ard.53.4.224","article-title":"Infection rate and use of antibiotics in patients with rheumatoid arthritis treated with methotrexate","volume":"53","author":"van der Veen","year":"1994","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib38","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1002\/art.23003","article-title":"The importance of the disease process and disease-modifying antirheumatic drug treatment in the development of septic arthritis in patients with rheumatoid arthritis","volume":"57","author":"Edwards","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib39","doi-asserted-by":"crossref","first-page":"1754","DOI":"10.1002\/art.22600","article-title":"Anti-tumor necrosis factor alpha therapy and the risk of serious bacterial infections in elderly patients with rheumatoid arthritis","volume":"56","author":"Schneeweiss","year":"2007","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib40","first-page":"639","article-title":"Methotrexate therapy in rheumatoid arthritis: a life table review of 587 patients treated in community practice","volume":"20","author":"Buchbinder","year":"1993","journal-title":"J Rheumatol"},{"issue":"Suppl. 12","key":"10.1016\/j.semarthrit.2017.02.003_bib41","first-page":"S35","article-title":"Toxicity of low dose methotrexate in rheumatoid arthritis","volume":"12","author":"Weinblatt","year":"1985","journal-title":"J Rheumatol Suppl"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib42","doi-asserted-by":"crossref","first-page":"272","DOI":"10.1002\/art.1780390214","article-title":"Pancytopenia secondary to methotrexate therapy in rheumatoid arthritis","volume":"39","author":"Gutierrez-Urena","year":"1996","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib43","doi-asserted-by":"crossref","first-page":"1430","DOI":"10.1001\/archinte.1989.00390060140032","article-title":"Methotrexate-associated, early-onset pancytopenia in rheumatoid arthritis","volume":"149","author":"Doolittle","year":"1989","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/0049-0172(85)90029-0","article-title":"Pancytopenia associated with low dose pulse methotrexate in the treatment of rheumatoid arthritis","volume":"15","author":"MacKinnon","year":"1985","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib45","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/j.autrev.2014.08.027","article-title":"Clinical characteristics and risk factors for low dose methotrexate toxicity: a cohort of 28 patients","volume":"13","author":"Kivity","year":"2014","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib46","doi-asserted-by":"crossref","first-page":"e0154744","DOI":"10.1371\/journal.pone.0154744","article-title":"Factors associated with myelosuppression related to low-dose methotrexate therapy for inflammatory rheumatic diseases","volume":"11","author":"Mori","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib47","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1016\/j.tripleo.2004.08.020","article-title":"Oral effects of low-dose methotrexate treatment","volume":"100","author":"Kalantzis","year":"2005","journal-title":"Oral Surg Oral Med Oral Pathol Oral Radiol Endod"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib48","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1111\/j.1445-5994.2009.01800.x","article-title":"Methotrexate: long-term safety and efficacy in an Australian consultant rheumatology practice","volume":"39","author":"Varatharajan","year":"2009","journal-title":"Intern Med J"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib49","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1136\/bmj.317.7152.180","article-title":"Disease activity and risk of lymphoma in patients with rheumatoid arthritis: nested case-control study","volume":"317","author":"Baecklund","year":"1998","journal-title":"Br Med J"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib50","doi-asserted-by":"crossref","first-page":"638","DOI":"10.1016\/0046-8177(94)90295-X","article-title":"Lymphoid neoplasms in patients with rheumatoid arthritis and dermatomyositis: frequency of Epstein-Barr virus and other features associated with immunosuppression","volume":"25","author":"Kamel","year":"1994","journal-title":"Hum Pathol"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib51","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/S0049-0172(97)80023-6","article-title":"Lymphoma in patients with rheumatoid arthritis: association with the disease state or methotrexate treatment","volume":"26","author":"Georgescu","year":"1997","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib52","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1016\/j.semarthrit.2013.08.003","article-title":"Comparative cancer risk associated with methotrexate, other non-biologic and biologic disease-modifying anti-rheumatic drugs","volume":"43","author":"Solomon","year":"2014","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib53","doi-asserted-by":"crossref","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for Cardiovascular Clinical Trials: a consensus report from the bleeding academic research consortium","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib54","first-page":"1164","article-title":"Methotrexate pneumonitis in rheumatoid arthritis: potential risk factors. Four case reports and a review of the literature","volume":"14","author":"Searles","year":"1987","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib55","unstructured":"National Cancer Institute Common Terminology Criteria for Adverse Events. \u3008http:\/\/evs.nci.nih.gov\/ftp1\/CTCAE\/CTCAE_4.03_2010-06-14_QuickReference_8.5x11.pdf\u3009. [accessed September 12, 2016]."},{"key":"10.1016\/j.semarthrit.2017.02.003_bib56","first-page":"1","article-title":"KDIGO Clinical Practice Guideline for Acute Kidney Injury","volume":"2","year":"2012","journal-title":"Kidney Int Suppl."},{"key":"10.1016\/j.semarthrit.2017.02.003_bib57","doi-asserted-by":"crossref","first-page":"1370","DOI":"10.1002\/art.20278","article-title":"Toward a better understanding of methotrexate","volume":"50","author":"Kremer","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib58","doi-asserted-by":"crossref","first-page":"1632","DOI":"10.1373\/49.10.1632","article-title":"HPLC determination of erythrocyte methotrexate polyglutamates after low-dose methotrexate therapy in patients with rheumatoid arthritis","volume":"49","author":"Dervieux","year":"2003","journal-title":"Clin Chem"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib59","doi-asserted-by":"crossref","first-page":"2766","DOI":"10.1002\/art.20460","article-title":"Polyglutamation of methotrexate with common polymorphisms in reduced folate carrier, aminoimidazole carboxamide ribonucleotide transformylase, and thymidylate synthase are associated with methotrexate effects in rheumatoid arthritis","volume":"50","author":"Dervieux","year":"2004","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib60","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1007\/s00216-012-6581-7","article-title":"Measuring methotrexate polyglutamates in red blood cells: a new LC-MS\/MS-based method","volume":"405","author":"den Boer","year":"2013","journal-title":"Anal Bioanal Chem"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib61","doi-asserted-by":"crossref","first-page":"305","DOI":"10.2217\/pgs.12.214","article-title":"Methotrexate pharmacogenetics in rheumatoid arthritis: a status report","volume":"14","author":"Malik","year":"2013","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib62","first-page":"414","article-title":"Intermediate homocysteinemia: a thermolabile variant of methylenetetrahydrofolate reductase","volume":"43","author":"Kang","year":"1988","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib63","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2217\/pgs.15.185","article-title":"Validation of a rapid test for HLA-B*58:01\/57:01 allele screening to detect individuals at risk for drug-induced hypersensitivity","volume":"17","author":"Nguyen","year":"2016","journal-title":"Pharmacogenomics"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib64","doi-asserted-by":"crossref","first-page":"e64683","DOI":"10.1371\/journal.pone.0064683","article-title":"Imputing amino acid polymorphisms in human leukocyte antigens","volume":"8","author":"Jia","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib65","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1086\/519795","article-title":"PLINK: a tool set for whole-genome association and population-based linkage analyses","volume":"81","author":"Purcell","year":"2007","journal-title":"Am J Hum Genet"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib66","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1038\/ng1847","article-title":"Principal components analysis corrects for stratification in genome-wide association studies","volume":"38","author":"Price","year":"2006","journal-title":"Nat Genet"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib67","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1002\/sim.2929","article-title":"Evaluating the added predictive ability of a new marker: from area under the ROC curve to reclassification and beyond","volume":"27","author":"Pencina","year":"2008","journal-title":"Stat Med."},{"key":"10.1016\/j.semarthrit.2017.02.003_bib68","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/sim.4085","article-title":"Extensions of net reclassification improvement calculations to measure usefulness of new biomarkers","volume":"30","author":"Pencina","year":"2011","journal-title":"Stat Med"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib69","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1136\/ard.2008.092668","article-title":"Optimal dosage and route of administration of methotrexate in rheumatoid arthritis: a systematic review of the literature","volume":"68","author":"Visser","year":"2009","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib70","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1002\/art.1780350603","article-title":"Effect of food on the bioavailability of low-dose methotrexate in patients with rheumatoid arthritis","volume":"35","author":"Oguey","year":"1992","journal-title":"Arthritis Rheum"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib71","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/BF02229705","article-title":"Thrombocytopenia in patients with rheumatoid arthritis on long-term treatment with low dose methotrexate","volume":"15","author":"Franck","year":"1996","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib72","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1111\/j.1445-5994.2009.02059.x","article-title":"Lack of association between elevated mean red cell volume and haematological toxicity in patients receiving long-term methotrexate for rheumatoid arthritis","volume":"40","author":"White","year":"2010","journal-title":"Intern Med J"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib73","first-page":"1832","article-title":"Acute lower respiratory tract infections in patients with rheumatoid arthritis","volume":"34","author":"Coyne","year":"2007","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2017.02.003_bib74","first-page":"CD000951","article-title":"Folic acid and folinic acid for reducing side effects in patients receiving methotrexate for rheumatoid arthritis","author":"Ortiz","year":"2000","journal-title":"Cochrane Database Syst Rev"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216304371?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017216304371?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2018,9,4]],"date-time":"2018-09-04T07:25:25Z","timestamp":1536045925000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017216304371"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,8]]},"references-count":74,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,8]]}},"alternative-id":["S0049017216304371"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2017.02.003","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2017,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Investigating methotrexate toxicity within a randomized double-blinded, placebo-controlled trial: Rationale and design of the Cardiovascular Inflammation Reduction Trial-Adverse Events (CIRT-AE) Study","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2017.02.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}